Agreed bid for AGI Therapeutics
9th Jan 2012 11:30
Pharmaceutical company AGI Therapeutics is to be swallowed up by Aravis Therapeutics, a recently formed Irish subsidiary of Altiva. The board of AGI is recommending an offer from Aravis which values AGI at about $8.4m (€6.6m). Aravis is offering 11.71 cents in cash for each AGI share they own. Pr
Read moreUnited Utilities boss raises £588,000 from share sale
28th Mar 2011 16:48
United Utilities chief executive Philip Green has raised £588,000 by selling 100,000 shares. Green still has 116,384 shares. The shares that were sold for 588p each were owned by Green and his wife Judy, who no longer holds any shares. In February, Green received 136,607 shares from the company'
Read moreLondon close: US spurs Footsie recovery
8th Sep 2010 16:36
Footsie put its weak start behind it to close with good gains, helped by buoyant trading on Wall Street. US shares recovered from losses yesterday that snapped a recent winning streak. Among the risers here was ARM Holdings. UBS has issued a downbeat assessment of the European semiconductor mark
Read moreLondon afternoon: ARM in line for Samsung boost
8th Sep 2010 14:28
Footsie emerged from the lunch-time session nursing a small gain, with the majority of the blue-chip index's constituents in positive territory. Chief among them was chip designer ARM Holdings. UBS has issued a downbeat assessment of the European semiconductor market but it has made an exception o
Read moreSmall caps round-up: Ark Therapeutics, Alkane Energy, CPL
8th Sep 2010 12:59
Speciality drug developer AGI Therapeutics posted narrower losses in the six months to June 30 and said it was on the look-out for 'external opportunities.' The company, which is developing treatments for gastrointestinal disorders and multiple sclerosis, saw pre-tax losses narrow to $3.1m from $9.
Read moreSmall caps round-up: Kefi, Mariana, New World Resources...
14th Apr 2010 12:42
An update on its activities in Saudi Arabia has lifted the share price of gold and copper explorer Kefi Minerals. A total of 21 exploration licenses have been lodged covering 2,100km2 the company said. Also in metals, Argentina and Chile-focused exploration and development group Mariana Resources i
Read moreAGI reviews strategy after trial failure
11th Jun 2009 09:01
Irish pharmaceutical firm AGI Therapeutics said it has started a review of its business strategy including alternative commercial applications for its main drug Rezular after it failed a key clinical trial. In Thursday's AGM statement AGI said it is reviewing Rezular, used for irritable bowel synd
Read moreLondon close: Footsie ends on low note
15th May 2009 16:29
London closed lower after a lacklustre afternoon session with losses on properties and travel companies outweighing gains on miners. Shocking figures from property giant Land Securities on Wednesday still cast a shadow over the real estate investment trusts (REITs). LandSecs leads the sector lowe
Read moreLondon afternoon: Travel companies trip Footsie
15th May 2009 14:10
London continues its gentle downward drift, with losses on properties and travel companies outweighing gains on miners. The market seems unlikely to get any sort of lift from Wall Street which is expected to open moderately weaker. Shocking figures from property giant Land Securities on Wednesday
Read moreAGI Therapeutics scraps Rezular after trial failure
15th May 2009 07:34
AGI Therapeutics is to scrap further development its irritable bowel syndrome treatment Rezular after a phase 3 trial indicated no real benefits. AGI said the trial showed no statistically significant differences between treatments in the primary endpoint of patient reported adequate relief of IBS
Read more